Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A uveal melanoma that arises from the iris. It is the most common primary malignant neoplasm of the iris. The majority arise in preexisting nevi.
Biomarker and diagnostic research for iris melanoma has been reported in the published literature.
2 clinical trials registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
134 publications have been identified in PubMed for iris melanoma. Research spans Review / Meta-Analysis (31%), Basic Science / Preclinical (25%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 33 | 31% |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 12:01 AM UTC
Laboratory research |
27 |
25% |
Disease patterns and progression | 13 | 12% |
Patient case studies | 12 | 11% |
Testing and diagnosis research | 10 | 9% |
Clinical study results | 9 | 8% |
New treatment approaches | 3 | 3% |
Other research | 1 | 1% |
Saakyan SV (2026). [PMID: 41847805](https://pubmed.ncbi.nlm.nih.gov/41847805/). *Vestn Oftalmol*. [Basic Science / Preclinical]
Djedouani M (2026). [PMID: 42121324](https://pubmed.ncbi.nlm.nih.gov/42121324/). *Med Phys*. [Basic Science / Preclinical]
Nissen K (2026). [PMID: 41062255](https://pubmed.ncbi.nlm.nih.gov/41062255/). *Br J Ophthalmol*. [Epidemiology / Natural History]
Mukundan A (2026). [PMID: 41316839](https://pubmed.ncbi.nlm.nih.gov/41316839/). *Ocul Immunol Inflamm*. [Review / Meta-Analysis]
Hiong A (2026). [PMID: 41633932](https://pubmed.ncbi.nlm.nih.gov/41633932/). *Clin Exp Ophthalmol*. [Review / Meta-Analysis]
Xu S (2026). [PMID: 41734832](https://pubmed.ncbi.nlm.nih.gov/41734832/). *Cancer Lett*. [Review / Meta-Analysis]
Roig-Ferreruela G (2026). [PMID: 42138585](https://pubmed.ncbi.nlm.nih.gov/42138585/). *Eur J Ophthalmol*. [Case Report / Case Series]
Chava S (2026). [PMID: 41366520](https://pubmed.ncbi.nlm.nih.gov/41366520/). *EMBO Mol Med*. [Basic Science / Preclinical]
Moshirfar M (2026). [PMID: 38261685](https://pubmed.ncbi.nlm.nih.gov/38261685/). *Unknown Journal*. [Review / Meta-Analysis]
de Sousa ACFC (2026). [PMID: 41315156](https://pubmed.ncbi.nlm.nih.gov/41315156/). *Vet Ophthalmol*. [Case Report / Case Series]